Clinical trials: Neurogenic Detrusor Overactivity
Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.
- Conditions
- Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic, Bladder Disorder, Neurogenic, Urinary Bladder Disorder, Neurogenic
- Trial name
- NCT01530620
- Testing
- Propiverine hydrochloride ER (extended release), Propiverine hydrochloride IR (immediate release)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Neurogenic Detrusor Overactivity
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Rec 0/0438 in subjects with neurogenic detrusor overactivity due to spinal cord injury
- Trial name
- NCT03482037
- Testing
- Rec 0/0438 1 mg or Rec 0/0438 2 mg
- Where
- 9 sites in Czechia, France and 2 more
- Volunteers
- 42 people
- Sponsor
- RECORDATI GROUP
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Overactive Bladder, Urinary Incontinence
Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.
The purpose of the study is to determine whether Botulinum-A toxin injected in the bladder muscle will help prevent the frequency and degree of urinary incontinence in Spinal Cord Injured and Multiple Sclerosis patients.
- Trial name
- NCT00262496
- Testing
- Botox
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Neurogenic Bladder Dysfunction
Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction
Many patients with neurological diseases suffer from neurogenic lower urinary tract dysfunction (NLUTD), which often severely impairs quality of life, due to urinary urgency with or without incontinence and voiding dysfunction.
- Trial name
- bTUNED (NCT04315142)
- Testing
- Experimental TTNS
- Where
- 12 sites in Belgium, Brazil and 2 more
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Overactive Bladder, Urinary Urge Incontinence
Over Active Bladder Instillation Study - Botox
The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly…
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia
- Trial name
- NCT00667095
- Testing
- Botox Instillation, DMSO Instillation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Spinal Cord Injuries
Transcutaneous Spinal Cord Stimulation With Bladder and Pelvic Floor Muscle Training
Spinal Cord Injury (SCI) disrupts signals between the brain and the rest of the body, this includes signals needed to control the bladder and bowels.
- Trial name
- NCT05504200
- Testing
- Bladder and Pelvic Floor Muscle Training
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- RNOH RIC
Urinary Incontinence
Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are…
- Trial name
- NCT02072928
- Testing
- botulinum toxin Type A
- Where
- 6 sites in Belgium
- Volunteers
- 55 people
- Sponsor
- Allergan
Urinary Incontinence, Urinary Bladder, Overactive
Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) or overactive bladder…
- Trial name
- NCT02010788
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 523 people
- Sponsor
- Allergan
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Urinary Bladder Neurogenic Dysfunction
Neuro-urological Outcome After Spinal Cord Injury
Most patients with spinal cord injury suffer from bladder dysfunction which may - especially in the long-term - impair renal function. Improved treatment during the last decades improved life expectancy and quality of life.
- Trial name
- NCT01297660
- Testing
- Video-urodynamic examination
- Where
- Switzerland
- Volunteers
- 55 people
- Sponsor
- Balgrist University Hospital
Neurogenic Detrusor Overactivity
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.
- Trial name
- Crocodile (NCT02751931)
- Testing
- Mirabegron
- Where
- 32 sites in Australia, Belgium and 17 more
- Volunteers
- 91 people
- Sponsor
- Astellas Pharma Europe B.V.
Spinal Cord Injuries, Neurogenic Detrusor Overactivity
TTNS in SCI Patients With Neurogenic Detrusor Overactivity
This is a prospective, single-arm, pilot study to assess effectiveness and tolerability of transcutaneous tibial nerve stimulation (TTNS) in managing neurogenic detrusor overactivity in spinal cord injury patients.
- Trial name
- NCT07785258
- Testing
- TTNS
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- National University Hospital, Singapore
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for…
- Trial name
- CONTENT2 (NCT02660359)
- Testing
- Botulinum toxin type A
- Where
- 82 sites in Argentina, Australia and 14 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Spinal Cord Injuries (SCI)
The Predictive Value of Lower Extremity Hypertonia on Neurogenic Detrusor Overactivity After Spinal Cord Injury
The goal of this observational study is to evaluate whether increased lower extremity muscle tone can serve as an independent predictor of neurogenic detrusor overactivity (NDO) in adult patients (aged 18-80 years) with upper…
- Trial name
- NCT07695662
- Volunteers
- 300 people
- Sponsor
- Shengjing Hospital
Detrusor Function, Overactive
Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and…
- Trial name
- RONDO (NCT01796548)
- Testing
- Oxybutinin Extended-Release
- Where
- 3 sites in Thailand
- Volunteers
- 17 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Neurogenic Detrusor Overactivity
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence).
- Trial name
- NCT05621616
- Testing
- mirabegron
- Where
- 3 sites in Philippines, Poland
- Volunteers
- 7 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Detrusor, Detrusor Hyperreflexia of Bladder
Onabotulinumtoxina Intradetrusorial Injections and NGF Expression
In the last years, botulinum toxin type A (onab/A) has been increasingly used as a treatment option for overactive bladder symptoms in patients affected by either neurogenic and idiopathic detrusor overactivity (DO).
- Trial name
- Onab/A-NGF (NCT01629433)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University Of Perugia
Neurogenic Detrusor Overactivity
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
- Trial name
- NCT01565694
- Testing
- Solifenacin succinate
- Where
- 21 sites in United States, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Astellas Pharma Europe B.V.